SABCS 2019 highlights

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer

The emerging role of immunotherapy for the treatment of early and advanced breast cancer

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients?

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer